Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Lymphoma, Large B-Cell, Diffuse × durvalumab × Clear all

Phase

Status

Completed 3 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Lung Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Triple Negative Breast Neoplasms 2 Pancreatic Neoplasms 2 Colorectal Neoplasms 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Small Cell Lung Carcinoma 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Oropharyngeal Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Microsatellite Instability 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large B-Cell, Diffuse 1 Liver Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Cancer Female 1 Adenocarcinoma of Lung 1 Adenocarcinoma Of Esophagus 1

Interventions

Rituximab 17 Cyclophosphamide 13 Etoposide 9 Vincristine 8 Prednisone 8 Doxorubicin 7 Cytarabine 6 Filgrastim 5 Radiotherapy 4 Peripheral Blood Stem Cell Transplantation 4 Bendamustine Hydrochloride 4 ibrutinib 3 fludarabine phosphate 3 Methotrexate 3 Carmustine 3 venetoclax 2 polatuzumab vedotin 2 pembrolizumab 2 loncastuximab tesirine 2 fludarabine 2 Vorinostat 2 Tacrolimus 2 Stem Cell Transplantation 2 Melphalan 2 Lenalidomide 2 Immunization, Passive 2 Ifosfamide 2 Gemcitabine 2 Dexamethasone 2 Carboplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03241017 2018-04-09

IDA-D

Insel Gruppe AG, University Hospital Bern

Phase 2 Withdrawn

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡